Science & Technology Review
|
2022, 40(1): 132-149
• Exclusive: Science and Technology Review in 2021 •
Retrospect and prospect of SARS-CoV-2 in 2021: Genetic mutation, cross-species transmission, and vaccine and drug in the COVID-19 pandemic
Full
YANG Jing1, RONG Wenwan1,2, HUAN Yu1,2, GONG Yuhuan1,2, BI Yuhai1,2
Affiliations
1. Center for Influenza Research and Early-warning (CASCIRE), CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China;
2. University of Chinese Academy of Sciences, Beijing 100049, China
Published: 2022-01-13
doi: 10.3981/j.issn.1000-7857.2022.01.008
Outline
In this review we address the classification, spatiotemporal distribution, and prevalence characteristics of SARS-CoV-2 variants, followed by a description of key mutations and their biological functions in virus variants. We also summarize the novel understandings on genetic origins and interspecies transmission risk of SARS-CoV-2 between humans and animals in 2021. Next, we describe the development and effectiveness of current vaccines and antiviral drugs in 2021, and the potential virus evolution under the pressure of insufficient immune protection provided by current vaccines. In the end, we put forward targeted suggestions on pandemic control, virus surveillance, and the development of highly effective vaccines and drugs.
SARS-CoV-2
/
virus mutation
/
cross-species transmission
/
vaccine
YANG Jing, RONG Wenwan, HUAN Yu, GONG Yuhuan, BI Yuhai.
Retrospect and prospect of SARS-CoV-2 in 2021: Genetic mutation, cross-species transmission, and vaccine and drug in the COVID-19 pandemic[J].
Science & Technology Review,
2022
, 40
(1)
: 132
-149
.
DOI: 10.3981/j.issn.1000-7857.2022.01.008
Year 2022 volume 40 Issue 1
PDF
713
89
Cite this Article
BibTeX
Article Info
doi: 10.3981/j.issn.1000-7857.2022.01.008
- Receive Date:2021-12-25
- Online Date:2022-02-18
- Published:2022-01-13